AltMountain

Lion Point Capital, LP

New York, NY · CRD 174322
Hedge fund manager

Lion Point Capital, LP is an SEC-registered investment adviser based in New York, NY that reports managing 2 hedge funds on Form ADV. It reports $480.6 million in regulatory assets under management. Its private funds, of all types, hold $480.5 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +14.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +90.4% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$480.6 millionForm ADV Item 5.F
Gross assets of private funds
$480.5 millionAll private fund types, Form ADV
Hedge funds managed
25 private funds in total
Employees
7Form ADV Item 5.A
Registration
SEC-registered adviserCRD 174322
Latest Form ADV
04/30/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+14.7%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+90.4%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$20.9 million35 positions, 2026-06-30
$91$141$190Q3 2024Q1 2025Q3 2025Q1 202613F est. $190S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+22.2%+14.8%
Q1 2026-6.1%-4.6%
Q4 2025+19.8%+2.4%
Q3 2025+39.7%+7.8%
Q2 2025+8.8%+10.4%
Q1 2025-15.8%-4.5%
Q4 2024+3.9%+2.1%
Q3 2024+4.1%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 34 share positions ($17,261,149) reported by Lion Point Capital, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Cue Biopharma Inc7.93%
  • Praxis Precision Medicines I7.51%
  • Royalty Pharma PLC7.24%
  • Fennec Pharmaceuticals Inc6.94%
  • Compass Pathways PLC5.77%
  • Moonlake Immunotherapeutics4.58%
  • Geron Corp4.12%
  • Milestone Pharmaceuticals In4.11%
  • Biohaven LTD4.00%
  • Syndax Pharmaceuticals Inc3.92%
StockValue% of 13F portfolioSharesShares vs prior quarter
Cue Biopharma Inc$1,369,2477.93%52,928Unchanged
Praxis Precision Medicines I$1,295,9747.51%4,450Unchanged
Royalty Pharma PLC$1,248,9047.24%21,400Unchanged
Fennec Pharmaceuticals Inc$1,197,4226.94%112,434Unchanged
Compass Pathways PLC$995,2005.77%80,000Unchanged
Moonlake Immunotherapeutics$789,7504.58%67,500Unchanged
Geron Corp$710,9404.12%578,000Unchanged
Milestone Pharmaceuticals In$709,8744.11%820,000Unchanged
Biohaven LTD$690,1954.00%51,700Unchanged
Syndax Pharmaceuticals Inc$676,8003.92%36,000Unchanged
Benitec Biopharma Inc$620,0003.59%62,000Unchanged
Disc Medicine Inc$530,2263.07%8,100Unchanged
Sarepta Therapeutics Inc$519,2703.01%28,500Unchanged
Kura Oncology Inc$492,6602.85%46,000Unchanged
Viatris Inc$490,8442.84%27,700Unchanged
Ardelyx Inc$439,9832.55%128,650Unchanged
Edgewise Therapeutics Inc$369,4602.14%9,100Unchanged
Uniqure NV$355,1522.06%14,700Unchanged
Azenta Inc$338,4331.96%9,700Unchanged
Pacira Biosciences Inc$338,1751.96%13,500Unchanged
Humacyte Inc$336,5051.95%650,000Unchanged
Bridgebio Pharma Inc$329,0001.91%5,000Unchanged
Janux Therapeutics Inc$328,3201.90%19,000Unchanged
Dyne Therapeutics Inc$289,9801.68%18,000Unchanged
Jasper Therapeutics Inc$269,7001.56%465,000Unchanged
Mineralys Therapeutics Inc$263,8651.53%10,500Unchanged
GH Research PLC$239,4961.39%10,200Unchanged
Rocket Pharmaceuticals Inc$226,1801.31%86,000Unchanged
Regenxbio Inc$200,2981.16%26,600Unchanged
Innoviva Inc$173,9221.01%8,200Unchanged
Arcutis Biotherapeutics Inc$138,7580.80%5,250Unchanged
Innate Pharma S A$132,2760.77%81,151Unchanged
Seres Therapeutics Inc$105,7600.61%31,570Unchanged
Spruce Biosciences Inc$48,5800.28%1,000Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 0 new positions, 1 sold out, 0 increased, 0 reduced and 34 unchanged.

Number of positions (a count, not dollars)

  • New positions0
  • Increased0
  • Unchanged34
  • Reduced0
  • Sold out1

Sold out

StockValue at Jun 30, 2026Shares held then
Lantheus Hldgs Inc$610,1705,500

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

Fund
Gross assets
Minimum
Owners
Adviser
Lion Point Master, LP
Cayman IslandsHedge fund
Gross assets$350M
Minimum$100K
Owners63
AdviserLion Point Capital, LP
Lion Point Life Sciences Partners, LP
Delaware, United StatesHedge fund
Gross assets$26.9M
Minimum$1.0M
Owners5
AdviserLion Point Capital, LP

As reported in the adviser's Form ADV filed Oct 8, 2024. Funds also listed from Form D are shown above.

Fund vehicles: feeder funds and single-deal vehicles (1)

Fund
Gross assets
Minimum
Owners
Adviser
Sunshine Spv LLC
Delaware, United StatesPrivate equity fund
Gross assets$133M
MinimumNone set
Owners27
AdviserLion Point Capital, LP

Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠